J&J’s Yondelis Leads New Wave Of Sarcoma Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for second-line approval in rare soft tissue sarcomas cites progression-free survival benefit, with no significant survival improvement, in Phase III trial.